We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Circadian Rhythm Genes Are Biomarkers for Predicting Risk of Preterm Birth

By LabMedica International staff writers
Posted on 17 Aug 2021
The CLOCK and CRY2 genes have been identified as useful biomarkers for predicting the likelihood that a pregnant woman will experience a preterm birth.
Previous studies have observed an association between maternal circadian rhythm disruption and preterm birth. More...
However, the underlying molecular mechanisms and the potential of circadian clock genes to serve as predictors of preterm birth remain unexplored.

Investigators at Michigan State University (East Lansing, USA) examined the association of 10 core circadian transcripts in maternal blood with spontaneous preterm births versus full term births using a nested case-control study design. For this study, maternal blood was sampled in trimesters two-three from women with spontaneous preterm births (n = 51) and full term births (n = 106), matched for five demographic variables.

Results revealed that in second trimester maternal blood, only CLOCK and CRY2 transcripts were significantly lower in spontaneous preterm births versus full term. In addition, the investigators identified 98 common pathways that were negatively or positively correlated with CLOCK and CRY2 expression.

CLOCK is a gene encoding a basic helix-loop-helix-PAS transcription factor that is believed to affect both the persistence and period of circadian rhythms. The CLOCK gene plays a major role as an activator of downstream elements in the pathway critical to the generation of circadian rhythms. In mammals, the proteins coded by the CRY1 and CRY2 genes act as light-independent inhibitors of CLOCK-BMAL1 components of the circadian clock.

“We were excited to discover lower mRNA levels in the CRY2 and CLOCK genes,” said senior author Dr. Hanne Hoffmann, assistant professor of animal science at Michigan State University. “Preterm births are common. If we know the mother is at risk for a preterm birth, her doctor can monitor her more closely. If we could measure women’s mRNA levels and tell them for their second or third pregnancies that they are not at risk for a preterm birth because their levels are higher (in a normal/healthy range), that would be such a comfort to the mothers who previously had a preterm birth. If I can help one baby make it to full term who was not supposed to, that would make my day.”

The preterm birth study was published in the June 18, 2021, online edition of the Journal Biology of Reproduction.

Related Links:

Michigan State University


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.